Clinical trial
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
NCT00385008 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00385008 |
|---|---|
| Title | TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine |
| Official title | An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine Disorders |
| Intervention type | Drug |
| Interventions | Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet |
| Enrollment | 20 |
| Start date | Sep 13, 2006 |
| Primary completion | Nov 24, 2006 |
| Completion | Nov 24, 2006 |
| First posted | Oct 6, 2006 |
| Last update posted | Feb 12, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: